Vicki Poole Hoffmann, PharmD
- 5Articles
- 12.4KReads
- 2005–2012Active
- 23Collaborators
- 60Citations
About
Vicki Poole Hoffmann, PharmD, has published extensively on the pharmacogenomics and treatment of weight gain associated with antipsychotic medications, particularly olanzapine and risperidone, in patients with schizophrenia and schizoaffective disorders. Her work includes analysis of genetic variants linked to drug response and evaluations of treatment algorithms aimed at preventing weight gain. Hoffmann has also contributed to research on insulin resistance and glucose metabolism in patients treated with antipsychotics, as well as wellness interventions for individuals with serious and persistent mental illness.
Publications
Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.
